While the impact of these findings in patients with PCa remains to be determined, combined with our previous studies and data from other laboratories, there is now accumulated and compelling evidence for targeting LRP5-mediated wnt/β-catenin pathway as a diagnostic, prognostic, and therapeutic target in patients with PCa and other common malignancies associated with skeletal metastases. This evidence concerns the gene LRP5 and posterior cortical atrophy.